 Chronic kidney disease (CKD) frequently coexists with diabetes, constituting diabetic kidney disease (DKD). 1 Gradual loss of renal function, as evidenced by increased albumin excretion rates and decreased glomerular filtration rate (eGFR), is associated with an increase in mortality and end-stage renal disease (ESRD). 2  Background therapies such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) only slow kidney disease progression. Improved treatments for DKD, therefore, should further reduce the rate of disease progression or even halt damage to the kidney and also should further reduce the risk for CV mortality and morbidity.
Background
 Chronic kidney disease (CKD) frequently coexists with diabetes, constituting diabetic kidney disease (DKD). 1 Gradual loss of renal function, as evidenced by increased albumin excretion rates and decreased glomerular filtration rate (eGFR), is associated with an increase in mortality and end-stage renal disease (ESRD). 2  Background therapies such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) only slow kidney disease progression. Improved treatments for DKD, therefore, should further reduce the rate of disease progression or even halt damage to the kidney and also should further reduce the risk for CV mortality and morbidity.
Objectives
 Finerenone (BAY94-8862) is a selective, potent and non-steroidal MRA which blocks the deleterious effects of aldosterone and is being developed for the treatment of patients with DKD.  An early health outcomes model was developed to investigate the implications of using finerenone in addition to background therapy for DKD, to identify key parameters, risk factors and outcomes drivers, and to support clinical development in designing the trial.
Methods
The model reflects the interdependency of risk factors, risk effects, disease states, and disease progression in DKD. It is based on finerenone"s effect to reduce albuminuria, 3 and on subsequent CV and renal outcomes. Structure:  A Markov cohort structure was applied to model disease history, treatment effects, and outcomes for DKD patients. It complies with the National Institute of Clinical Excellence (NICE) modeling guidelines; the perspective is third-party payer with US settings over a 40-year time horizon  The model includes a total of 16 health states, focusing on CKD, CV disease, and chronic heart failure (CHF). State transitions in the model are a function of various population characteristics and risk factors. A set of patients with DKD and albuminuria are followed from the start of the simulation through the progression of disease states until death.
Results
The model predicts, as outcome of finerenone treatment, major reductions of progression of DKD and risk of transition to ESRD, and moderate reductions of risk of CVD and CHF events and death (Table 2) .
 The clinical and economic results for the four distinct subpopulations based on levels of UACR and eGFR reveal that greater benefit is seen when finerenone treatment is started in DKD patients who are in more advanced stages of their disease.  In contrast, when it comes to reducing CV events finerenone treatment gives highest benefit to DKD patients in the earlier stages of their disease.
 The breakdown of costs and savings by subpopulations (Fig. 3) shows increasing cost offsets for renal replacement therapy (RRT) when starting treatment in advanced disease patients (macro-albuminuria, CKD3/4). In comparison savings for CV and HF events were small.
Conclusion
 The model suggests that finerenone is an effective treatment option for DKD patients, primarily by virtue of delay of ESRD and renal death. This is particularly true if treatment is initiated for patients after they have progressed to either macro-albuminuria or CKD stage 3, as represented by the two pivotal trial populations "FIGARO" and "FIDELIO".  The factors that most influence clinical outcomes of finerenone treatment are disease severity at start of treatment and the treatment effect of finerenone itself.  The model results will be validated once clinical trial data as well as data from real life utilization become available.
Discussion
 This study investigated the implications for patient relevant outcomes of finerenone treatment in DKD on top of background therapy in four distinct subpopulations defined by levels of UACR and eGFR.  For optimal patient benefits (reduced risk of entering ESRD and increased health related quality of life) and optimal healthcare resource utilization (cost savings on RRT), the optimal time point to begin finerenone treatment appears to be when patients have progressed to macro-albuminuria (focus of the clinical trial "FIDELIO") or to CKD stage 3 (focus of both clinical trials).  Reduced CV events and CV mortality are greatest when finerenone treatment is started in early disease states (focus of clinical trial "FIGARO").  Limitations and uncertainties of the model findings are around (1) the correlation between albuminuria and outcomes; this correlation has been shown in retrospect but not in prospective studies; (2) outcome predictors, due to the absence of phase 3 data on finerenone"s clinical effectiveness to change clinical outcomes; (3) availability of data for progression to macroalbuminuria, due to low numbers of patients in the NHANES database. CVD -cardiovascular disease, eGFR -glomerular filtration rate, HbA1c -glycated hemoglobin, MI -Myocardial infarction, SBPsystolic blood pressure, UACR -urinary albumin-creatinine ratio
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Cost and utilities:
 Utilities for hypertension, diabetes, CKD3/4, CVD, CHF, and ESRD are based on published evidence 4,5  Chronic health state costs 6, 7, 8 and acute event costs 6,9 are based on published research. Pharmaceutical costs are drawn from the British National Formulary. Efficacy:  Clinical efficacy of finerenone affects the reduction of initial albuminuria which in turn impacts the progression of DKD and morbidity and mortality; 40% UACR reduction for microalbuminuria, 50% UACR reduction for macro-albuminuria are based on findings from the phase 2a trial. 3 It is assumed finerenone is not applied in ESRD patients.
Comparators:
 Two comparators are considered: background therapy (includes treatment with ACEIs or ARBs and other anti-hypertensives, and statins) +/-finerenone Health Outcomes:  Primary outcomes are incremental cost per quality adjusted life year (QALY) and per life year (LY)  Additional clinical outcomes include the number of events (CKD stage 3, ESRD, renal mortality after ESRD, and fatal and non-fatal CVD and CHF)
Population:
 Adults age 50+ with DKD and albuminuria (urinary-albuminuria-creatinine ratio, UACR≥30), including CVD, but without ESRD or CHF. Baseline population characteristics are based on patients in the NHANES dataset 1999-2008. The NHANES data has been weighted in order to reflect the race and smoking distributions of the UKPDS population, which included 31% smokers and 7.6% Afro-Caribbean race. Because the race categories in NHANES and UKPDS do not align, Afro-Caribbean in UKPDS were taken equivalent to "black" in NHANES.
Abstract ID# 58716 / PUK3 ISPOR 18th Annual European Conference November 2015, Milano, Italy  In contrast, the model predicts that patients in early disease states, i.e. with lower albuminuria levels and also higher eGFR values, would experience comparatively high risk reduction of CV death through treatment with finerenone (Fig. 7) . These patients are represented by the FIGARO trial and the minority (10-20%) of the FIDELIO trial.
 Furthermore, the model predicts that more advanced DKD patients would experience increased gains of quality adjusted life years (QALYs) due to treatment with finerenone ( Fig. 6 ). These patients are represented by both trial populations  Decreased kidney function with poor prognosis and risk for major outcomes is independently evidenced by increased UACR and/or decreased eGFR. 10 Two ongoing phase 3 trials ("FIGARO" and "FIDELIO") will examine whether finerenone can both reduce CV mortality/morbidity and slow progression of kidney disease in DKD patients. 11 Patients in the FIGARO trial have high albuminuria (micro-albuminuria) and are at elevated risk of CV mortality and morbidity. Patients in the FIDELIO trial have very high albuminuria (macro-albuminuria) and are at elevated risk of subsequent renal disease, including ESRD, but also of CV mortality and morbidity.  Sensitivity analyses were performed in order to provide insight into how key parameters impact the clinical outcomes and costs of treating DKD.
Graphic from Levey et al. Kidney International (2011) 80, 17-28 "FIDELIO" study "FIGARO" study "FIDELIO" study "FIGARO" study At each model cycle, a fraction of the patients makes a transition from one health state to the next. In any health state, patients may experience no change, disease progression of albuminuria or eGFR decline, a CVD or CHF event, or background mortality (Fig. 2) .  A two-way sensitivity analysis (Fig. 4) , depicted as a two-dimensional representation of the eGFR/UACR kidney disease severity and risk continuum, 10 shows that the renal replacement therapy (RRT) cost savings are a function of disease severity and UACR levels. Starting treatment with finerenone for patients with advanced DKD, with reduced eGFR below 60ml/min (CKD3) and macro-albuminuria, appears to generate the highest RRT cost savings. These patients are represented by the FIDELIO trial population (green box in Fig. 4 ).
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 Along that line, the absolute risk reduction for a patient to succumb to renal death is highest when finerenone treatment is started in advanced DKD, i.e. reduced eGFR around 60ml/min and macro-albuminuria. This is due to reduced rate of entering ESRD (not shown). Again, these patients are represented by the FIDELIO trial population (green box in Fig. 5 ) but also by the FIGARO trial population (blue box in Fig. 5 ).
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